Our Science

On Aug. 10, 2018, the United States Food and Drug Administration (FDA) approved our licensor-- Alnylam’s ONPATTRO? (patisiran) as the first ever FDA-approved RNAi medicine. This historical approval marks the arrival of an entirely new class of therapeutics — RNAi Medicines.

RNAi is a naturally occurring cellular mechanism of regulating gene expression and is mediated by small interfering RNAs (siRNAs).


We aim to develop ASC06 as the first systematically delivered therapeutic drug to treat liver cancer by using RNA interference, a breakthrough approach to drug discovery and development. ASC06 has been designed to silence two genes critical for growth of liver cancer cells — vascular endothelial growth factor (“VEGF”) and kinesin spindle protein (“KSP”).  ASC06 has completed phase I and phase I extension clinical trials, which have shown that 50% of patients who received ≥0.7 mg/kg dose achieved stable disease and one patient achieved a complete response. ASC06 is safe and well-tolerated by patients.




* Intracellular double stranded RNA is processed by the “dicer” complex pathway (A) to produce siRNAs which become integrated into a multi-subunit protein complex, the RNAi induced silencing complex (RISC) (B), which guides the siRNAs to the target mRNA sequence (C). The siRNA duplex unwinds, and the antisense strand remains bound to RISC and directs degradation of the complementary mRNA sequence (D), resulting in target protein suppression (E).

nba比分 球探体育比分4.8 辽宁11选5 足彩北单比分直播 浙江十一选五 球探篮球比分即时比分 广西快乐10分 踢球者190足球即时指数 山西泳坛夺金 188足球即时比分网 上海时时乐 亿客隆彩票首页 山西快乐十分 浙江飞鱼 雪缘棒球比分网 湖北十一选五 3g体育比分网